Xavier Roblin

31PUBLICATIONS
50CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Rheumatology and arthritisEpidemiological modellingClinical chemistry (incl. diagnostics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Mar 24, 2026
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Emmanuel Niyigena, Yannick Hoffert, Waqqas Afif

|Dec 02, 2024
One Concentration Does Not Fit All: It Is Time to Personalize the Therapeutic Range of Infliximab in Crohn Disease.

Bénédicte Franck, Camille Tron, Marie-Clémence Verdier

|Feb 28, 2023
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.

Mathurin Fumery, Stéphane Nancey, Jérôme Filippi

|Dec 19, 2022
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.

Mathurin Fumery, Antoine Defrance, Xavier Roblin

|Apr 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.

Niels Vande Casteele, William J Sandborn, Brian G Feagan

|Mar 01, 2022
Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.

Xavier Roblin, Pauline Veyrard, Laetitia Bastide

Pageof 6

Frequent Collaborators

12 joint publications

Stephane Paul

10 joint publications

Laurent Peyrin-Biroulet

7 joint publications

Aurelien Amiot

7 joint publications

Guillaume Bouguen